RE:RE:RE:RE:Completely unprepared for this outcomeThey've always mentioned the possibility that if sort1 is doing it's thing to internalize most of the PDC right in the tumor and bypassing resistance in a safe way, they could play around with the "window" opportunities. Worth asking in next call if part of their ongoing lab work was doing that. Have to figure the lab guys are doing it now though to get them some info. No doubt, all the pre-clinical looked very logical and ticked all the boxes, the FDA even agreed. Translating that into clinics is their test.
scarlet1967 wrote: ca39cc52-e553-4a81-9b8d-a217ad2558cc
ca39cc52-e553-4a81-9b8d-a217ad2558cc
“Explore different dosing schedules (weekly, intermittent vs continual) in order to increase the therapeutic window in terms of efficacy and safety.”
Again they didn’t make a decision of that magnitude particularly for a small business which has to allocate their limited resources wisely in matter of hours so they did start and should have the started figuring their contingency plan during the course of the trial based on their observations.
I personally would applaud them if they had shared as much as they could showing that this company is prepared for the eventual challenges instead they decided …..